Venlafaxine Hydrochloride

Venlafaxine Hydrochloride is an oral antidepressant agent of the Serotonin-Norepinephrine Reuptake Inhibitor class. Venlafaxine Hydrochloride has been studied for the treatment of panic disorder, post-traumatic stress disorder, and the treatment of hot flashes in patients who cannot or do not want to take hormone replacement therapy. Venlafaxine Hydrochloride is an inhibitor with a double role- Venlafaxine Hydrochloride inhibits serotonin reuptake at select receptors and, unlike the pure selective serotonin reuptake inhibitors (SSRIs), inhibits the reuptake of norepinephrine. Venlafaxine Hydrochloride appears to be effective in treating patients with melancholia, a severe form of depression. The side effect and drug interaction profile of Venlafaxine Hydrochloride is very similar to that of the SSRIs. Venlafaxine Hydrochloride does not exhibit MAO inhibition activity, yet Venlafaxine Hydrochloride should not be used in patients who are receiving or have recently received MAOI therapy.

Venlafaxine Hydrochloride’s innovator is American Home Products (Wyeth Ayerst) and appears world-wide under the brand name Effexor.

Like the tricyclics, Venlafaxine Hydrochloride and its active metabolite, O-desmethylvenlafaxine (ODV), exert their antidepressant effects by inhibiting the reuptake of both serotonin and norepinephrine. In vivo, Venlafaxine Hydrochloride blocks both reuptake processes, with a potency greater for the 5-HT than for the NE reuptake process. Like the SSRI's, Venlafaxine Hydrochloride appears to act preferentially on certain serotonin receptors in vivo, but mechanisms have not been precisley defined. Both Venlafaxine Hydrochloride and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine. Venlafaxine Hydrochloride and ODV do not exert activity at histaminergic, muscarinic, or alpha1-adrenergic receptors in vitro, which accounts for its lack of anticholinergic, sedative, and cardiovascular side effects frequently observed with the tricyclic antidepressants. However, despite the claims of minimal muscarinic receptor activity, anticholinergic-related side effects may still occur with Venlafaxine Hydrochloride.

Venlafaxine Hydrochloride appears in the following formulation and dosage:
Tablets: 25mg, 37.5mg, 50mg, 75mg, 100mg, 225mg
Capsule ER (Effexor XR): 37.5mg, 75mg, 150mg
Tablet:  ER- 37.5mg, 75mg, 150mg, 225mg

General data on Venlafaxine Hydrochloride Active Pharmaceutical Ingredient

CAS Registry: 99300-78-4
ATC: N06AX16
Molecular Formula: C17H27NO2, HCl
Molecular Weight: 313.9
Pharmacopoeias: In Eur.

Ph. Eur. 5.5: Venlafaxine Hydrochloride is a white or almost white powder. It exhibits polymorphism. Venlafaxine Hydrochloride is freely soluble in water and in methyl alcohol; soluble in dehydrated alcohol; slightly soluble or practically insoluble in acetone.

TAPI's Venlafaxine Hydrochloride Pharmaceutical Ingredient

TAPI's Venlafaxine Hydrochloride Active Pharmaceutical Ingredient is produced in Assia Chemical Industries Limited - Teva Tech site in Beer Sheva, Israel.

Venlafaxine Hydrochloride is produced by TAPI by Organic synthesis and considered to be medium-high volume Active Pharmaceutical Ingredient.
 
TAPI's Venlafaxine Hydrochloride has unique features that might be advantage for final dosage development. TAPI has filed several patent applications for Venlafaxine Hydrochloride. Please, see table below for issued patents and pending applications.

2008 Available DMF: U.S. DMF, EU CTD and CEP.

TAPI provide full service on Venlafaxine Hydrochloride and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Venlafaxine Hydrochloride. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Venlafaxine Hydrochloride.

Other products, in the group of CNS PREPARATIONS - Antidepressants available on TAPI's portfolio are:  Aripiprazole, Mirtazapine, Nefazodone Hydrochloride, Trazodone Hydrochloride and Ziprasidone Hydrochloride.Contact us today for information on these products.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients